TY - JOUR T1 - Intolarence of pirfenidone and its associated factors in the real world JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA786 VL - 48 IS - suppl 60 SP - PA786 AU - Shunsuke Teraoka AU - Daichi Fujimoto AU - Munehiro Ito AU - Yoshihiro Nakagawa AU - Jiro Ito AU - Mariko Kogo AU - Yuki Sato AU - Kato Ryoji AU - Kazuma Nagata AU - Atsushi Nakagawa AU - Kojiro Otsuka AU - Yukimasa Hatachi AU - Keisuke Tomii Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA786.abstract N2 - [Background] Despite of evidences showing the benefit of pirfenidone, their use is frequently associated with some adverse effect which could result in discontinuation. We investigated the reason of intolerance and to identify predictors of tolerability to pirfenidone.[Methods] This retrospective study comprised 76 patients with pulmonary fibrosis who were treated with pirfenidone from January 2011 to January 2016. We evaluated the adverse effect affecting patient continuation of a stable maintenance dose.[Result] Nineteen of 76 failed to receive pirfenidone 1200mg/day. Anorexia was reported by eleven patients, which was largest population among the intolerance group. In the comparison to the tolerant group who succeeded in continuing more than 1200mg/day for a month, there was a significant association to prophylactic administration of dopamine receptor antagonists (38% vs 9%, p = 0.04).[Conclusion] This study reveal that anorexia is the most common reason for discontinuation of pirfenidone in the real world. Prophylactic administration of dopamine receptor antagonists provides a significant reduction of anorexia from pirfenione. ER -